Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2024-04-24 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '云南沃森生物技术股份有限公司2024 年第一季度报告' which translates to 'Yunnan Watson Biotechnology Co., Ltd. 2024 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial changes for the first quarter of 2024. The document includes comprehensive financial metrics, shareholder information, and notes on company activities such as share repurchases and financing plans. The length is substantial (15,000 characters) and it contains actual financial statements and substantive financial data for a period shorter than a full fiscal year, specifically a quarterly report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-04-24 Chinese
第五届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the 5th Board of Directors of Yunnan Watson Biotechnology Co., Ltd. It includes details about the meeting date, attendance, and voting results on two main agenda items: approval of the 2024 Q1 report and election of members to the Board's Sustainable Development Committee. The document explicitly states it is a "董事会会议决议公告" (Board meeting resolution announcement). It does not contain the full quarterly report or detailed financial data but rather announces the board's approval of the report and committee appointments. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board decisions. The document length is short and it is not the report itself, so it is not an Interim/Quarterly Report (IR).
2024-04-24 Chinese
第五届监事会第十五次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the review and approval of the company's 2024 first quarter report. It states that the Supervisory Board has audited the quarterly report and confirms its compliance and accuracy. The document itself does not contain the full quarterly report or detailed financial data but rather announces the approval and provides a link to the full report on an external site. The document length is short (770 characters), and it serves as an announcement of the report's approval rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2024-04-24 Chinese
关于变更回购股份用途并注销及减少公司注册资本暨通知债权人的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Yunnan Watson Biotechnology Co., Ltd. regarding the change in the use of repurchased shares and the cancellation and reduction of the company's registered capital. It includes details about the board and shareholder meetings where the proposal was approved, the specifics of the share cancellation and capital reduction, and instructions for creditors to declare their claims within a specified period. The document is a formal notification to creditors about the company's capital change and related legal rights, not a financial report or detailed management discussion. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy statement or voting result announcement. The content fits best with a capital/financing update as it concerns changes in share repurchase usage and registered capital reduction. The document length is short (1584 characters), and it contains substantive information about the capital change, not just a report publication announcement or regulatory filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-04-22 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd. It includes voting results on various agenda items such as the 2023 annual report, financial statements, board reports, amendments to company rules, and other corporate governance matters. The document also mentions the meeting date, attendance, voting methods, and legal opinions on the meeting's validity. The content is focused on the outcomes of the AGM rather than the full annual report or financial statements themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7290 characters) and detailed voting results support this classification with high confidence.
2024-04-19 Chinese
北京国枫律师事务所关于公司2023年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, voting procedures, and results of the 2023 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd. It details the legality and validity of the meeting process and voting outcomes, including approval of various reports and proposals. The document does not contain the actual annual report or financial statements but rather certifies the AGM procedures and results. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results from the AGM. The document length is about 5916 characters, which is sufficient for a detailed voting results announcement but not a full annual report. Therefore, the correct classification is DVA with high confidence.
2024-04-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.